Clinical Trials Logo

Epistaxis clinical trials

View clinical trials related to Epistaxis.

Filter by:

NCT ID: NCT02963129 Not yet recruiting - Epistaxis Clinical Trials

Treatment of Nasal Staphylococcus Aureus Colonization in Patients With HHT

Start date: June 2017
Phase: Phase 3
Study type: Interventional

Compare the frequency of epistaxis and quality of life related to nasal bleeding in patients with HHT colonized with sataphylococo before and after being treated with mupirocin ointment.

NCT ID: NCT02930941 Terminated - Epistaxis Clinical Trials

Topical Intranasal Tranexamic Acid for Epistaxis in the Emergency Department

Start date: February 2016
Phase: Phase 4
Study type: Interventional

It is estimated that epistaxis results in 4.5 million emergency department visits per year throughout the United States. Due to the adverse effects of standard treatment options for epistaxis, tranexamic acid (TXA) may be considered an attractive option. In previous studies, when used with nasal packing, TXA showed faster time to control of bleeding. The goal of this study is to determine the efficacy and safety of topical intranasal TXA applied via atomizer for patients with epistaxis who present to the emergency department.

NCT ID: NCT02677467 Not yet recruiting - Clinical trials for Cardiovascular Disease

Correlation Between Epistaxis and Cardiovascular Disease

CBECD
Start date: March 2016
Phase: N/A
Study type: Observational [Patient Registry]

Investigators examine blood-pressure variance, several cardiovascular risk factors of patient with epistaxis. As a result of collected data, investigators look into correlation between epistaxis and hypertensive cardiovascular disorder.

NCT ID: NCT02638012 Completed - Epistaxis Clinical Trials

Prospective Pilot Study of Floseal for the Treatment of Anterior Epistaxis in Patients With (HHT)

Start date: December 2015
Phase: N/A
Study type: Interventional

Current management strategies for severe and recurrent epistaxis secondary to Hereditary hemorrhagic telangiectasia (HHT) include surgical procedures, and uncomfortable nasal packing, both of which are often only short-term solutions. Floseal® may provide a non-invasive and less painful treatment option for epistaxis in HHT patients. This hemostatic agent has been shown to be an effective intraoperative hemostatic agent in a number of surgical procedures including endoscopic sinus surgery. It has also been shown to be favorable over nasal packing at controlling acute anterior epistaxis. Though the efficacy of using Floseal® for epistaxis in HHT patients has been proven anecdotally in the literature it has yet to be proven in a prospective clinical trial. The results of this pilot study will provide insight into the efficacy of using Floseal® in the management of severe epistaxis in HHT patients and to assist in the development of a full-scale prospective clinical trial.

NCT ID: NCT02517294 Completed - Epistaxis Clinical Trials

, "Mucosal Injury During Nasotracheal Intubation for Dental Procedures in Children-does the Tube Design Matter?"

Start date: June 2015
Phase: N/A
Study type: Interventional

Comparison is made between standard nasotracheal tubes and a specially designed nasotracheal tube during nasotracheal intubation in children undergoing general anesthesia for dental surgery.

NCT ID: NCT02488135 Completed - Epistaxis Clinical Trials

Management of Persistent Epistaxis Using Floseal Hemostatic Matrix

Start date: July 1, 2015
Phase: N/A
Study type: Interventional

Nosebleeds that persist even after adequate traditional nasal packing may require aggressive treatment strategies to stop bleeding. Currently these strategies include a surgical approach to cut off blood supply to the vessel that is bleeding. FloSeal Hemostatic matrix is a gel like medical therapy that is inserted into the nose and is engineered to stop bleeding in severe cases, possibly avoiding the need for surgery. In this study the investigators will randomize patients to either receive FloSeal Hemostatix matrix or traditional nasal packing as a treatment for severe nosebleeds. The main outcome will be whether the investigators are able to stop bleeding with FloSeal or traditional packing alone and whether additional measures are necessary to stop the bleeding. The investigators will also perform a patient comfort survey and cost analysis. Even if FloSeal has equal effectiveness in treating nosebleeds as traditional packing, if it is much more comfortable for patients then it may be the favourable treatment.

NCT ID: NCT02484716 Completed - Clinical trials for Telangiectasia, Hereditary Hemorrhagic

Efficacy of a Timolol Nasal Spray as a Treatment for Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT) - (TEMPO)

TEMPO
Start date: June 2015
Phase: Phase 2
Study type: Interventional

Timolol is a nonselective β-blocker commonly used in the treatment of glaucoma. Recently it has been used topically for the treatment of superficial hemangiomas. Because of its potential mechanism of action, it is possible that timolol could also be useful for the treatment of epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT). Moreover a case was reported in 2012 showing an improvement of nosebleeds with the use of topical nasal timolol. The aim of the study is to evaluate timolol nasal spray efficacy in HHT. The main objective of this trial is to evaluate, 3 months after the end of the treatment, the efficacy on the duration of nosebleeds of a 4 weeks timolol intranasal treatment in HHT patients with nosebleeds (>20 min/month). Secondary objectives are to evaluate the tolerance, the efficacy at 6 months after the end of the treatment, and the efficacy on anemia and on clinical parameters (nosebleeds, quality of life and blood transfusions). This is a prospective double blind phase II study, randomized versus placebo using an allocation ratio of 1:1. A total of 58 patients will be included. The product (solution with timolol at 0.5% or placebo) is self-administered by the patient with a posology of one spray (50 µL) in each nostril twice a day for 28 consecutive days.

NCT ID: NCT02466464 Withdrawn - Epistaxis Clinical Trials

Microporous Polysaccharide Hemospheres Epistaxis

Start date: January 1, 2015
Phase: N/A
Study type: Interventional

The purpose of this study is to compare a new treatment for nosebleeds to the treatment that has been used for many years.

NCT ID: NCT02389959 Completed - Epistaxis Clinical Trials

Intranasal Bevacizumab for HHT-Related Epistaxis

Start date: August 4, 2014
Phase: Phase 4
Study type: Interventional

This is a randomized, controlled, double-blind, placebo-controlled trial of intranasal Avastin (bevacizumab) injection versus saline control for control of HHT-related epistaxis when used in conjunction with bipolar electrocautery.

NCT ID: NCT02370381 Completed - Epistaxis Clinical Trials

Hemoglobin and INR Out of Nose Blood

Start date: February 2015
Phase: N/A
Study type: Observational

Nose bleeding (epistaxis) is a common emergency. It is often difficult to estimate blood loss and the current hemoglobin of patients. In patients with oral anticoagulation, it is important to measure the level of hemodilution. Several situations with the importance of the fast determination of these parameters have been identified in previous studies [1,2]. The blood sampling from the venous punction is the standard in these investigations. However, this requires the corresponding painful puncture and also the time required at the laboratory. Since many patients present themselves with active bleeding, it is obvious that this blood could be used for determining the following parameters: Hemoglobin and INR/Quick. The nose blood can be analyzed with commercial rapid test devices. If these devices could generate same or similar results and after further validation of the method, painful punctures could be waived.